Profound Medical (PROF) Projected to Announce Quarterly Earnings on Thursday

Profound Medical (NASDAQ:PROF) is projected to release its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect the company to post earnings of ($0.22) per share and revenue of $4.75 million for the quarter. Interested persons can check the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

Profound Medical (NASDAQ:PROF) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.19) EPS for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.05. The company had revenue of $5.34 million during the quarter, compared to the consensus estimate of $4.85 million. Profound Medical had a negative net margin of 206.76% and a negative return on equity of 78.88%. On average, analysts expect Profound Medical to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Profound Medical Stock Performance

PROF stock opened at $7.24 on Thursday. Profound Medical has a one year low of $3.76 and a one year high of $8.95. The firm has a market cap of $263.10 million, a PE ratio of -5.84 and a beta of 0.73. The firm’s 50 day moving average price is $6.85 and its 200-day moving average price is $6.82.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on PROF. Raymond James Financial upgraded Profound Medical from an “outperform” rating to a “strong-buy” rating and set a $11.00 price target for the company in a report on Monday. Weiss Ratings cut shares of Profound Medical from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, July 14th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Profound Medical has a consensus rating of “Moderate Buy” and a consensus target price of $11.50.

Institutional Investors Weigh In On Profound Medical

Institutional investors have recently modified their holdings of the company. FIL Ltd raised its holdings in shares of Profound Medical by 16.7% in the 4th quarter. FIL Ltd now owns 2,200,000 shares of the company’s stock valued at $17,270,000 after buying an additional 315,000 shares during the period. Rosalind Advisors Inc. boosted its holdings in Profound Medical by 54.4% during the 4th quarter. Rosalind Advisors Inc. now owns 1,068,955 shares of the company’s stock valued at $8,413,000 after acquiring an additional 376,770 shares during the period. Raymond James Financial Inc. boosted its holdings in Profound Medical by 5.5% during the 2nd quarter. Raymond James Financial Inc. now owns 941,879 shares of the company’s stock valued at $5,557,000 after acquiring an additional 49,000 shares during the period. Alyeska Investment Group L.P. acquired a new position in Profound Medical in the 4th quarter valued at about $5,340,000. Finally, Royal Bank of Canada grew its position in Profound Medical by 3.5% in the 1st quarter. Royal Bank of Canada now owns 435,997 shares of the company’s stock valued at $2,537,000 after acquiring an additional 14,795 shares in the last quarter. 47.86% of the stock is owned by institutional investors and hedge funds.

About Profound Medical

Profound Medical Corp is a medical technology company headquartered in Toronto, Canada, that specializes in the development and commercialization of minimally invasive therapeutic solutions using magnetic resonance–guided ultrasound ablation. The company’s proprietary platform delivers focused ultrasound energy to targeted tissue under real-time MR imaging, offering a non-incisional alternative to traditional surgical approaches.

The company’s lead product, the TULSA-PRO system, is designed for the treatment of prostate conditions, including localized prostate cancer and benign prostatic hyperplasia.